Prospective Population Study on Candidemia in Spain
CANDIPOP
1 other identifier
observational
730
1 country
29
Brief Summary
The aim of this study is to describe the epidemiology of fungal blood infections in Spain (with emphasis on the incidence, fungal species distribution and antifungal susceptibility). The study is to be performed in five big cities which represent different geographic areas: Barcelona, Bilbao, Madrid, Sevilla and Valencia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2013
29 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 5, 2010
CompletedFirst Posted
Study publicly available on registry
November 8, 2010
CompletedStudy Start
First participant enrolled
March 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2013
CompletedApril 23, 2013
April 1, 2013
Same day
November 5, 2010
April 22, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Describe fungemia epidemiology in Spain
Recollection of demographic variables (age, gender and ethnic origin); clinical variables (background diseases, other coinfections, treatment received, etc) and microbiological information of the isolate.
1 year
Secondary Outcomes (5)
Describe differences among cities and institutions
1 year
Definition of risk factors
1 year
Determination of the fungal isolates susceptibility to fluconazole, voriconazole, caspofungine, anidulafungine, micafungine and anfotericine B
1 year
Correlation between fungemia with a diminished susceptibility fungal strain and clinical evolution
1 year
Correlation between reference and commercial microbiological methods
1 year
Study Arms (1)
Fungemia
Patients with a fungal isolate from a blood culture
Interventions
Eligibility Criteria
All patients with Candida sp or other fungal isolate obtained from a blood sample (fungemia episode)
You may qualify if:
- Fungal isolate obtained from blood sample
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fundacion SEIMC-GESIDAlead
- Astellas Pharma Inccollaborator
- Gilead Sciencescollaborator
- Merck Sharp & Dohme LLCcollaborator
- Pfizercollaborator
Study Sites (29)
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
Hospital de Barcelona
Barcelona, Barcelona, 08034, Spain
Hospital Vall d'Hebrón
Barcelona, Barcelona, 08035, Spain
Hospital Clinic i Provincial
Barcelona, Barcelona, 08036, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, 08041, Spain
Hospital Sant Joan de Dèu
Esplugues de Llobregat, Barcelona, 08950, Spain
Hospital Fundación de Alcorcón
Alcorcón, Madrid, 28922, Spain
Hospital de la Princesa
Madrid, Madrid, 28006, Spain
Hospital Gregorio Marañon
Madrid, Madrid, 28007, Spain
Hospital del Niño Jesús
Madrid, Madrid, 28009, Spain
Hospital Infanta Leonor
Madrid, Madrid, 28032, Spain
Hospital Ramon y Cajal
Madrid, Madrid, 28034, Spain
Fundación Jiménez Díaz
Madrid, Madrid, 28040, Spain
Hospital Clínico San Carlos
Madrid, Madrid, 28040, Spain
Hospital 12 de Octubre
Madrid, Madrid, 28041, Spain
Hospital La Paz
Madrid, Madrid, 28046, Spain
Hospital Puerta de Hierro Majadahonda
Majadahonda, Madrid, 28222, Spain
Hospital San Juan de Dios del Aljarafe
Bormujos, Seville, 41930, Spain
Hospital Virgen de Macarena
Seville, Seville, 41009, Spain
Clínica Sagrado Corazón
Seville, Seville, 41013, Spain
Hospital Virgen del Rocío
Seville, Seville, 41013, Spain
Hospital Nuestra Señora de Valme
Seville, Seville, 41014, Spain
Hospital La Fe
Valencia, Valencia, 46009, Spain
Hospital Clínico de Valencia
Valencia, Valencia, 46010, Spain
Hospital General de Valencia
Valencia, Valencia, 46014, Spain
Hospital Doctor Peset
Valencia, Valencia, 46017, Spain
Hospital de Cruces
Barakaldo, Vizcaya, 48903, Spain
Hospital de Basurto
Basurto, Vizcaya, 48013, Spain
Hospital de Galdakao-Usansolo
Galdakao, Vizcaya, 48960, Spain
Related Publications (1)
Puig-Asensio M, Fernandez-Ruiz M, Aguado JM, Merino P, Lora-Pablos D, Guinea J, Martin-Davila P, Cuenca-Estrella M, Almirante B. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections. Antimicrob Agents Chemother. 2016 May 23;60(6):3291-300. doi: 10.1128/AAC.00195-16. Print 2016 Jun.
PMID: 26976872DERIVED
Biospecimen
Fungal strains obtained from blood cultures.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Manuel Cuenca, MD, PhD
Instituto de Salud Carlos III
- STUDY DIRECTOR
Belen Padilla, MD
Hospital Gregorio Marañon
- STUDY DIRECTOR
Isabel Ruiz, MD
Hospital Vall d'Hebron
- STUDY DIRECTOR
Jose Garnacho-Montero, MD
Hospital Virgen del Rocio
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 5, 2010
First Posted
November 8, 2010
Study Start
March 1, 2013
Primary Completion
March 1, 2013
Study Completion
March 1, 2013
Last Updated
April 23, 2013
Record last verified: 2013-04